Interview with Dominique Demolle , Co-founder & CEO, Aepodia
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Address: Avenue Albert Einstein 2A
1348 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 39 20 11
Web: http://http/www.aepodia.com
Aepodia S.A. (spin-off of a top 10 US Pharma Company) was created in March 2007 by a group of experts in early-phase clinical development. Since then, our company has grown and built a strong and a worldwide reputation in the early clinical drug development sector. We have established solid and effective collaborations with world pharmaceutical leaders, as well as with small biotech companies. The management and staff members have a background in pharmaceutical development that allows us to understand sponsor requirements and challenges and to meet their needs in an optimal way.
Our headquarters are located in Louvain-La-Neuve, Belgium, with offices in Paris-La Défense, France. Thanks to our strategic location in the center of Europe, we can cover the European phase I units. We also support clinical trials in the United-States and Singapore and provide easy access to patients.
Aepodia is a CRO sponsor representative providing customized services in Phase I/II clinical trials and in clinical development of Medical devices.
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent…
Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on…
Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down…
Writing in the special December 2022 edition of DIA’s Global Forum magazine, Eli Lilly’s Mark Mayer, Pfizer’s Nick Sykes and Julie O’Brien, and the EFPIA’s Sini Eskola, Magda Chlebus, and…
Writing in the DIA Global Forum’s special November 2022 issue on the Digital Virtuous Loop Karin Van Baelen and Susan Sandler – both of Janssen – and AbbVie’s Álmath Spooner…
The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed…
EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new…
In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate…
Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health…
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
See our Cookie Privacy Policy Here
